Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Merck (MRK) through the VizualStocks API.
Sales of Merck veterinary medicines, vaccines and health-management products for livestock and companion animals. The portfolio includes the Bravecto parasiticide line as well as animal identification, traceability and monitoring products.
animalHealthRevenueProfit from Merck's livestock and companion-animal business after all segment cost of sales and directly incurred selling, administrative and research expenses. Corporate costs, financing, restructuring and acquisition-related items are not allocated to this measure.
animalHealthSegmentProfitConsolidated Merck sales derived from Asia-Pacific markets other than China and Japan, spanning Pharmaceuticals, Animal Health and Other revenue. China and Japan are reported as separate geographies.
asiaPacificExcludingChinaAndJapanRevenueConsolidated Merck sales derived from China across its Pharmaceutical, Animal Health and Other revenue categories. China is separated from the remainder of Asia Pacific in Merck's geographic table.
chinaRevenueConsolidated sales derived from Merck customers in Europe, the Middle East and Africa across Pharmaceuticals, Animal Health and Other revenue.
europeMiddleEastAndAfricaRevenueConsolidated Merck sales derived from Japan across its Pharmaceutical, Animal Health and Other revenue categories. Japan is separated from the remainder of Asia Pacific in Merck's geographic table.
japanRevenueConsolidated sales derived from Merck customers in Latin America across Pharmaceuticals, Animal Health and Other revenue.
latinAmericaRevenueConsolidated Merck sales derived from markets outside its separately reported U.S., EMEA, Latin America, China, Japan and remaining Asia-Pacific categories. This geographic residual is distinct from Merck's product-level Other revenue category.
otherGeographicRevenueRevenue outside Merck's Pharmaceutical and Animal Health segments, primarily third-party manufacturing, miscellaneous corporate revenue, revenue hedging and out-licensing milestones. This is not sales of a reportable Other product segment.
otherProductRevenueMiscellaneous corporate profit and operating profit or loss from third-party manufacturing arrangements. Merck calls this Other profits rather than a reportable segment, and it excludes the much larger unallocated research, financing, amortization, restructuring and corporate-cost reconciliation.
otherSegmentProfitSales from Merck's human-health medicines and vaccines, including oncology products led by Keytruda, vaccines such as Gardasil, and cardiometabolic, respiratory, hospital, immunology and diabetes therapies. The figure also includes Merck's share of certain alliance-product economics.
pharmaceuticalRevenueProfit from Merck's human-health medicines and vaccines after standard product costs and selling and administrative expenses incurred directly by the segment. It excludes central human-health research, remaining manufacturing and corporate costs, financing, restructuring, amortization and acquisition-related charges.
pharmaceuticalSegmentProfitConsolidated sales derived from Merck customers in the United States across Pharmaceuticals, Animal Health and Other revenue. Product sales are reported after U.S. chargebacks and rebates owed to private and public benefit plans.
unitedStatesRevenue